Compare Biogen Inc (BIIB) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Biogen Inc trades at $193.52 (market cap $28.34B), while First Trust NASDAQ 100 Technology Index Fund trades at $311.33. Which is the better fit depends on your goals.
| BIIB | QTEC | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $335.74 |
52-Week Low | $122.68 | $207.03 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
QTEC trades at $312.20, down 2.75% today amid neutral technical signals and bearish moving average pressure. The ETF provides equal-weighted exposure to Nasdaq-100 technology stocks, with recent news highlighting its role in the AI and semiconductor sector. Support levels at $310 and $307 provide near-term downside protection while resistance sits at $316 and $319.
The technology sector ETF faces headwinds from valuation concerns in AI-related stocks but maintains strategic positioning for long-term tech growth. Key risks include sector concentration and market volatility, while institutional interest remains steady given the fund's targeted exposure to leading technology companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
